RUNX1 and acute myeloid leukemia: Relapsed AML had usually acquired at least one relapse-specific mutation (e.g., in FLT3, ASXL1 or RUNX1), whereas mutations in NPM1 and in signaling genes (e.g., NRAS, KIT, PTPN11) were less frequent [17,18].